22 May 2013
Keywords: nexavar, excluded, japan, dpc, chuikyo, central, social
Article | 05 May 2008
Japan's Chuikyo (the Central Social Insurance Medical Council) has decided to exclude Nexavar (sorafenib), an anticancer drug marketed in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 April 2008
5 May 2008
21 May 2013
© 2013 thepharmaletter.com